Y-Biologics Inc.

Industry

  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
See more in Biomedtracker

Latest on Y-Biologics Inc.

Scrip

Navigator Medicines Emerges With $100m, Autoimmune Candidate

 
• By Joseph Haas

Navigator Medicines unveiled its plans to develop novel medicines for complex, heterogeneous autoimmune diseases on 27 August, revealing that it has raised $100m in series A funding from RA Capital M

Scrip

Asia Deal Watch: ProGen To Partner With Rani On GLP-2 Agonist In Obesity

 
• By Joseph Haas, Jung Won Shin, and Lisa Takagi

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. ProGen Partners With Rani To Devel

Scrip

The Hunt For Big Fish: How KDDF Is Helping Create Korean Deals

 
• By Jung Won Shin

As Korean biopharma firms, particularly bioventures, are suffering from a sharp decline in financing and licensing deals, the role of the state-supported Korea Drug Development Fund (KDDF) is becoming

Scrip

Asia Deal Watch: India’s Encube Targeted As Private Equity Interest In CDMOs Grows

 
• By Anju Ghangurde, Joseph Haas, Ian Haydock, and Jung Won Shin

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Quadria-Led Consortium Takes Foothold I